Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allovectin-7 in recurrent metastatic melanoma
NCT00395070Phase 3Completed
- Sponsor
- Vical Incorporated
- Start
- Oct 2006
- Primary completion
- Mar 2012
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of allovectin-7 in melanoma (2 arms), sponsored by Vical Incorporated. Primary endpoint: Overall Response Rate at 24 weeks. Started Oct 2006; status: completed.
02
Drugs
allovectin-7
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00395070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395070.